Key regions: India, Japan, France, Brazil, South Korea
The demand for Anti-Fibrinolytic Drugs in Kenya has been on the rise in recent years.
Customer preferences: Anti-Fibrinolytic Drugs are used to control bleeding in patients suffering from various medical conditions. In Kenya, these drugs are commonly used in surgeries, particularly in cases where blood loss is expected to be significant. Due to the country's high prevalence of infectious diseases such as HIV/AIDS and malaria, there is a constant demand for surgical interventions, which has led to an increased demand for Anti-Fibrinolytic Drugs.
Trends in the market: The Anti-Fibrinolytic Drugs market in Kenya is expected to grow steadily in the coming years. This growth can be attributed to the increasing number of surgeries being performed in the country, as well as the rising prevalence of chronic diseases such as diabetes and cancer. Additionally, the government's efforts to improve healthcare infrastructure and increase access to medical services have contributed to the growth of the market.
Local special circumstances: One of the major challenges facing the Anti-Fibrinolytic Drugs market in Kenya is the high cost of these drugs. Many patients cannot afford the drugs, which limits their access to necessary medical treatment. Additionally, there is a lack of awareness among patients and healthcare providers about the benefits of Anti-Fibrinolytic Drugs, which has led to underutilization of these drugs in some cases.
Underlying macroeconomic factors: Kenya's economy has been growing steadily in recent years, which has led to an increase in disposable income and improved access to healthcare services. Additionally, the government has been investing heavily in healthcare infrastructure, which has led to improved access to medical services for many Kenyans. These factors have contributed to the growth of the Anti-Fibrinolytic Drugs market in Kenya.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
